Erlotinib

Generic Name
Erlotinib
Brand Names
Tarceva
Drug Type
Small Molecule
Chemical Formula
C22H23N3O4
CAS Number
183321-74-6
Unique Ingredient Identifier
J4T82NDH7E
Background

Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...

Indication

Erlotinib is indicated for:

The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.

Associated Conditions
Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
Associated Therapies
-
Clinical Trials
Related News

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

First Posted Date
2020-10-05
Last Posted Date
2020-10-20
Lead Sponsor
Guangdong Association of Clinical Trials
Target Recruit Count
272
Registration Number
NCT04575415
Locations
🇨🇳

Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

First Posted Date
2020-07-02
Last Posted Date
2020-07-02
Lead Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Target Recruit Count
168
Registration Number
NCT04455594
Locations
🇨🇳

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

First Posted Date
2020-06-29
Last Posted Date
2024-12-09
Lead Sponsor
Genentech, Inc.
Target Recruit Count
498
Registration Number
NCT04449874
Locations
🇺🇸

UPMC - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Univ of Calif, San Francisco; Breast Cancer Center, San Francisco, California, United States

and more 72 locations

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

First Posted Date
2020-04-10
Last Posted Date
2022-10-26
Lead Sponsor
Ulrik Lassen
Target Recruit Count
300
Registration Number
NCT04341181
Locations
🇩🇰

Aarhus University Hospital, Aarhus, Denmark

🇩🇰

Rigshospitalet, Copenhagen, Denmark

🇩🇰

Odense University Hospital, Odense, Denmark

and more 4 locations

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

First Posted Date
2019-11-15
Last Posted Date
2021-11-24
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
5
Registration Number
NCT04165031
Locations
🇦🇺

Linear Clinical Research Ltd, Nedlands, Western Australia, Australia

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Indiana Univ Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States

and more 1 locations

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients with Central Nervous System (CNS) Metastases

First Posted Date
2018-08-31
Last Posted Date
2024-10-15
Lead Sponsor
Alpha Biopharma (Jiangsu) Co., Ltd.
Target Recruit Count
492
Registration Number
NCT03653546
Locations
🇨🇳

China site, Tianjin, China

🇨🇳

China site 0123, Jinan, Shandong, China

🇰🇷

Korea Site, Seoul, Korea, Republic of

and more 3 locations

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

First Posted Date
2018-04-13
Last Posted Date
2024-06-14
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
528
Registration Number
NCT03498521
Locations
🇦🇺

Northern Cancer Institute, St Leonards, New South Wales, Australia

🇦🇺

Blacktown Hospital, Blacktown, New South Wales, Australia

🇫🇮

Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland

and more 134 locations

Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.

First Posted Date
2018-03-09
Last Posted Date
2020-03-05
Lead Sponsor
Hikma Pharmaceuticals LLC
Target Recruit Count
9
Registration Number
NCT03460678
Locations
🇯🇴

King Hussein Cancer Center (KHCC), Amman, Jordan

🇱🇧

American University of Beirut Medical Center, Beirut, Lebanon

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

First Posted Date
2017-09-29
Last Posted Date
2024-11-12
Lead Sponsor
Canadian Cancer Trials Group
Target Recruit Count
720
Registration Number
NCT03297606
Locations
🇨🇦

Verspeeten Family Cancer Centre, London, Ontario, Canada

🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

🇨🇦

BCCA - Kelowna, Kelowna, British Columbia, Canada

and more 7 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy